MedTrace Logo

To Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gasterectomy

NCT05410535 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 431

Last updated 2024-06-28

No results posted yet for this study

Summary

Of those patients who participated in PEGASUS-D FAS clinical trial, patient must sign the informed consent form in order to participate in this extension study.

The medical records of the patients will be reviewed throughout the study.

Conditions

Interventions

DRUG

Patients who continued UDCA 300mg medication

patients who continued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial

OTHER

Patients who discontinued UDCA 300mg prescription

patients who discontinued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Principal Investigators

  • DoJoong Park · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-15
Primary Completion
2022-10-28
Completion
2022-10-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05410535 on ClinicalTrials.gov